Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Lewy body dementia

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Neuropsychological assessment has featured prominently over the past 30 years in the characterization of dementia associated with Alzheimer disease (AD). Clinical neuropsychological methods have identified the earliest, most definitive cognitive and behavioral symptoms of illness, contributing to the identification, staging, and tracking of disease. With increasing public awareness of dementia, disease detection has moved to earlier stages of illness, at a time when deficits are both behaviorally and pathologically selective. For reasons that are not well understood, early AD pathology frequently targets large-scale neuroanatomical networks for episodic memory before other networks that subserve language, attention, executive functions, and visuospatial abilities. This chapter reviews the pathognomonic neuropsychological features of AD dementia and how these differ from "normal," age-related cognitive decline and from other neurodegenerative diseases that cause dementia, including cortical Lewy body disease, frontotemporal lobar degeneration, and cerebrovascular disease.

What this study adds

Evidence grade: Low

This is a narrative review. This review describes how neuropsychological testing identifies and tracks the cognitive and behavioral symptoms of Alzheimer's disease, often starting with episodic memory. It is about assessment and diagnosis, not about treating, curing, or preventing the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Weintraub, S., Wicklund, A. H., & Salmon, D. P. (2012). The neuropsychological profile of Alzheimer disease. Cold Spring Harbor perspectives in medicine. https://doi.org/10.1101/cshperspect.a006171

Vancouver

Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harbor perspectives in medicine. 2012. doi:10.1101/cshperspect.a006171. PMID: 22474609.

BibTeX

@article{weintraub2012-22474609,
  author  = {Weintraub, S. and Wicklund, A. H. and Salmon, D. P.},
  title   = {{The neuropsychological profile of Alzheimer disease}},
  journal = {Cold Spring Harbor perspectives in medicine},
  year    = {2012},
  doi     = {10.1101/cshperspect.a006171},
  pmid    = {22474609},
  url     = {https://doi.org/10.1101/cshperspect.a006171}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review describes how neuropsychological testing identifies and tracks the cognitive and behavioral symptoms of Alzheimer's disease, often starting with episodic memory. It is about assessment and diagnosis, not about treating, curing, or preventing the disease.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year left out, no data; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 46 of the 94 points it could be judged on, which is 49 of 100. Total 49 of 100.46 of the 94 points we could judge = 49 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 46 of the 94 points we could judge it on, which is 49 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Cold Spring Harbor perspectives in medicine)
Journal's citation record 2 / 4 Cold Spring Harbor Perspectives in Medicine: journal h-index 197 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 570 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 35.6 citations a year over 16 year(s) since 2012
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 3 / 6 Cited by 15 other studies in this library
Still being cited 3 / 4 Cited 123 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author David P. Salmon: h-index 107 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California San Diego: institution h-index 1,852 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 22474609)
Free to read 0 / 2 Behind a paywall — scores zero
Points 46 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 94 points we could judge it on is 49 out of 100.
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 55.

Later studies that cite this one

15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Lewy body dementia from nearby years

Also in Lewy body dementia

39 studies in the library are filed under Lewy body dementia with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Lewy body dementia hub.

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →